NCT02733237

Brief Summary

To investigate whether intranasal oxytocin (40 IU) treatment can influence the tolerance of infidelity in males and females.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Apr 2015

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2015

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

March 30, 2016

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 11, 2016

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

March 6, 2017

Status Verified

March 1, 2017

Enrollment Period

1 year

First QC Date

March 30, 2016

Last Update Submit

March 2, 2017

Conditions

Healthy

Keywords

oxytocininfidelity

Outcome Measures

Primary Outcomes (1)

  • attitude towards fidelity and infidelity of potential mate.

    attitude is measured by the rating scores for likability, attractiveness and trustworthiness

    1 hour

Study Arms (4)

male oxytocin group

EXPERIMENTAL

male subjects with oxytocin treatment

Drug: oxytocin treatment

female oxytocin group

EXPERIMENTAL

female subjects with oxytocin treatment

Drug: oxytocin treatment

male placebo group

PLACEBO COMPARATOR

male subjects with placebo treatment

Drug: placebo treatment

female placebo group

PLACEBO COMPARATOR

female subjects with placebo treatment

Drug: placebo treatment

Interventions

oxytocin treatmentDRUG

intranasal administration of oxytocin (40 IU)

female oxytocin groupmale oxytocin group
placebo treatmentDRUG

intranasal administration of placebo (40 IU)

female placebo groupmale placebo group

Eligibility Criteria

Age19 Years - 28 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

  • history of head injury;
  • pregnant,menstruating,taking oral contraceptives
  • medical or psychiatric illness.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China, Sichuan

Chengdu, Sichuan, 611731, China

Location

Study Officials

  • Keith Kendrick, Dr.

    University of Electronic Science and Technology of China

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 30, 2016

First Posted

April 11, 2016

Study Start

April 1, 2015

Primary Completion

April 1, 2016

Study Completion

May 1, 2016

Last Updated

March 6, 2017

Record last verified: 2017-03

Locations

CN(1)